Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Literature DB >> 16847462

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

Jeffrey A Engelman¹, Ji Luo, Lewis C Cantley.

Abstract

Phosphatidylinositol 3-kinases (PI3Ks) evolved from a single enzyme that regulates vesicle trafficking in unicellular eukaryotes into a family of enzymes that regulate cellular metabolism and growth in multicellular organisms. In this review, we examine how the PI3K pathway has evolved to control these fundamental processes, and how this pathway is in turn regulated by intricate feedback and crosstalk mechanisms. In light of the recent advances in our understanding of the function of PI3Ks in the pathogenesis of diabetes and cancer, we discuss the exciting therapeutic opportunities for targeting this pathway to treat these diseases.

Entities: Disease Gene Mutation Species

Mesh：

Substances：

Year: 2006 PMID： 16847462 DOI： 10.1038/nrg1879

Source DB: PubMed Journal: Nat Rev Genet ISSN： 1471-0056 Impact factor: 53.242

Keyword Cloud
Cited

1244 in total

1. Escherichia coli succinic thiolinase. Stoichiometry of phosphorylation and coenzyme A binding.

Authors: C M Bowman; J S Nishimura
Journal: J Biol Chem Date: 1975-07-25 Impact factor: 5.157

2. New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.

Authors: Jerzy Lasota; Artur Kowalik; Anna Felisiak-Golabek; Sebastian Zięba; Zeng-Feng Wang; Markku Miettinen
Journal: Appl Immunohistochem Mol Morphol Date: 2019-01

3. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.

Authors: Sang Hyun Lee; George Poulogiannis; Saumyadipta Pyne; Shidong Jia; Lihua Zou; Sabina Signoretti; Massimo Loda; Lewis Clayton Cantley; Thomas M Roberts
Journal: Proc Natl Acad Sci U S A Date: 2010-06-01 Impact factor: 11.205

4. Phosphatase and tensin homologue (PTEN) regulates synaptic plasticity independently of its effect on neuronal morphology and migration.

Authors: Margaret Sperow; Raymond B Berry; Ildar T Bayazitov; Guo Zhu; Suzanne J Baker; Stanislav S Zakharenko
Journal: J Physiol Date: 2011-12-06 Impact factor: 5.182

5. The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.

Authors: Cullen M Taniguchi; Jonathon Winnay; Tatsuya Kondo; Roderick T Bronson; Alexander R Guimaraes; José O Alemán; Ji Luo; Gregory Stephanopoulos; Ralph Weissleder; Lewis C Cantley; C Ronald Kahn
Journal: Cancer Res Date: 2010-06-08 Impact factor: 12.701

6. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.

Authors: Hailing Cheng; Pixu Liu; Fan Zhang; Erbo Xu; Lynn Symonds; Carolynn E Ohlson; Roderick T Bronson; Sauveur-Michel Maira; Emmanuelle Di Tomaso; Jane Li; Andrea P Myers; Lewis C Cantley; Gordon B Mills; Jean J Zhao
Journal: Cancer Res Date: 2013-12-09 Impact factor: 12.701

The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism.

1. Escherichia coli succinic thiolinase. Stoichiometry of phosphorylation and coenzyme A binding.

2. New Mechanisms of mTOR Pathway Activation in KIT-mutant Malignant GISTs.

3. A constitutively activated form of the p110beta isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice.

4. Phosphatase and tensin homologue (PTEN) regulates synaptic plasticity independently of its effect on neuronal morphology and migration.

5. The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.

6. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.

Review 7. PI3K/mTORC1 activation in hamartoma syndromes: therapeutic prospects.

Review 8. The PIK3CA gene as a mutated target for cancer therapy.

9. Membrane Recruitment as a Cancer Mechanism: A Case Study of Akt PH Domain.

Review 10. Beyond chemotherapy: targeted therapies in ovarian cancer.